Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
Srihari Gopal,1 Jagadish Gogate,1 Katalin Pungor,2 Edward Kim,3 Arun Singh,1 Maju Mathews1 1Janssen Research and Development, LLC, Titusville, NJ, USA; 2Medical Affairs, EMEA, Janssen-Cilag, Neuss, Germany; 3Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, USACorrespondence: Srih...
Guardado en:
Autores principales: | Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6dc97ae0664487db7899f4e59a3904f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020) -
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018) -
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
por: Mathews M, et al.
Publicado: (2020) -
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019) -
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)